More sarcoma patients are beating the odds with pembrolizumab! This immunotherapy can change the treatment for limb sarcomas ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

PITTSBURGH — Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...

Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and were PD-(L)1 Experienced Achieved Significant Tumor Volume Reductions and Prolonged Progression Free Survival ...

Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Third Quarter 2024 Results Conference Call. At ...

In a real-world diverse population of patients with early triple-negative breast cancer (TNBC), 34% of patients who received ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

Updated findings from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study (NCT04221945) show the survival advantages of ...